Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.17 EUR
Change Today +0.03 / 0.72%
Volume 780.0
As of 11:18 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

biosynex (ALBIO) Snapshot

Open
€4.14
Previous Close
€4.14
Day High
€4.17
Day Low
€4.01
52 Week High
04/28/14 - €7.05
52 Week Low
11/19/14 - €2.88
Market Cap
6.7M
Average Volume 10 Days
907.6
EPS TTM
€-1.09
Shares Outstanding
1.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSYNEX (ALBIO)

Related News

No related news articles were found.

biosynex (ALBIO) Related Businessweek News

No Related Businessweek News Found

biosynex (ALBIO) Details

Biosynex Societe Anonyme, a diagnostic company, provides diagnostic tests and vitro diagnostic products in France. The company develops immunochromatographic and immunofiltration tests for use in the areas of obstetrics, parasitology, virology, autoimmunology, and bacteriology. It serves healthcare professionals, such as biologists, clinicians, nurses, and midwives. The company is based in Strasbourg, France.

33 Employees
Last Reported Date: 05/1/14

biosynex (ALBIO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biosynex (ALBIO) Key Developments

Biosynex Reports Earnings Results for the Second Half and Year of 2014

Biosynex reported earnings results for the second half and year of 2014. Second-half revenue was up 5.4% on the year to EUR 2.9 million. For the year, the company reported net loss of EUR 1.4 million, in line with the result booked a year earlier. Operating loss was also flat on the year, at EUR 1.5 million. Revenue fell 7% year-on-year to EUR 5.2 million.

Biosynex Announces Earnings Results for the Full Year of 2013

Biosynex announced earnings results for the full year of 2013. For the year, the company reported net loss expand to EUR 1.36 million (USD 1.9 million) in 2013 from EUR 710,000 in 2012. Operating loss widened to EUR 1.49 million from EUR 740,000. Revenues remained stable at EUR 5.57 million.

Biosynex Launches IMMUNOQUICK® DENGUE

BIOSYNEX launched IMMUNOQUICK® DENGUE. IMMUNOQuick® Dengue, the new CE-marked test of BIOSYNEX allowing an early and quick diagnosis of the Dengue infection for better patient care.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALBIO:FP €4.17 EUR +0.03

ALBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALBIO.
View Industry Companies
 

Industry Analysis

ALBIO

Industry Average

Valuation ALBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYNEX, please visit www.biosynex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.